WO2023233405A1 - Compositions de soins de la peau - Google Patents

Compositions de soins de la peau Download PDF

Info

Publication number
WO2023233405A1
WO2023233405A1 PCT/IL2023/050559 IL2023050559W WO2023233405A1 WO 2023233405 A1 WO2023233405 A1 WO 2023233405A1 IL 2023050559 W IL2023050559 W IL 2023050559W WO 2023233405 A1 WO2023233405 A1 WO 2023233405A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
combination
kit
composition
extract
Prior art date
Application number
PCT/IL2023/050559
Other languages
English (en)
Inventor
Dror Cohen
Meital PORTUGAL COHEN
Alexandra Blinderman
David Barak
Ze'evi Ma'or
Original Assignee
Ahava - Dead Sea Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ahava - Dead Sea Laboratories Ltd. filed Critical Ahava - Dead Sea Laboratories Ltd.
Publication of WO2023233405A1 publication Critical patent/WO2023233405A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • This invention relates to skin care compositions and utilizing same e.g., as skin lucent and anti-pigmentation.
  • the present invention provides a composition and/or a combinations and/or a kit for use in improving one or more of skin glow, lucent, radiance, anti-pigmentation, even tone and clear.
  • the present invention provides a composition and/or a combination and/or a kit for use in inhibiting and/or reducing skin melanin formation.
  • the present invention provides a composition and/or a combination and/or a kit for use a method of inhibiting and/or reducing skin melanin formation, wherein said method comprises topical application of said composition and/or combination and/or the ingredients comprised within said kit onto the skin of a subject.
  • the present invention provides the use of a composition and/or a combination according to the invention in the manufacture of a pharmaceutical formulation and/or a skin care formulation (e.g., for the intended use/s as indicated herein above and below).
  • the present invention provides one or more of a lotion, an ointment, a gel, a mask, a toner, an essence, a shampoo, a moisturizer, a sunscreen, a cream, a stick, a spray, an aerosol, foam, a paste, a mousse, a solid, semisolid, or a liquid make-up, a foundation, and an eye make-up comprising the composition and/or the combination according to the invention.
  • Figure 2 represents melanin secretion observed with B 16 melanocyte cell culture without (black) and in the presence (grey, white) of the whitening agent Arbutin at various time points.
  • the at least one Dead Sea extract, the at least one extract of the plant Rumex, and the at least one Thioredoxin polypeptide may be present in different compositions/formulations e.g., in a form that is suitable for administration in conjunction with the other.
  • the present invention provides a combination comprising (i) at least one Dead Sea extract, (ii) at least one extract of the plant Rumex, and (iii) at least one Thioredoxin polypeptide, wherein each of components (i), (ii) and (iii), independently of the other, is formulated in admixture with one or more of an adjuvant, an excipient, a diluent or a carrier (being a pharmaceutically acceptable and/or a cosmetically acceptable adjuvant, excipient, diluent or carrier).
  • the present invention provides a kit comprising
  • the concentrations of these ions are, as assessed by a water analysis carried out by the Geological Survey of Israel:
  • the Dead Sea Water comprises: Calcium (Ca +2 ) 34,000 - 40,000 mg/L
  • the concentrations provided herein above and below with respect to the components of the kit of the invention are at least 2 times, at times at least 3 times, event at times at least 5 times higher than the concentrations detailed herein above and below [(e.g., 5.0 % times 2, 3 or 5 i.e., 10 %, 15 % or 25 %, respectively), (e.g., 4.0 % times 2, 3 or 5 i.e., 8.0 %, 12.0 % or 20.0 %, respectively) (e.g., 3.0 % times 2, 3 or 5 i.e., 6.0 %, 9.0 % or 12.0%, respectively) (e.g., 2.5 % times 2, 3 or 5 i.e., 5.0%, 7.5 % or 12.5%, respectively), and upon concomitant topical application the dilution thereof results with a value as detailed herein above and below.
  • concentrations provided herein above and below with respect to the components of the kit of the invention are at least 2 times, at times at least 3
  • the concentration of the Dead Sea extract (e.g., Dead Sea water) in the composition and/or formulation and/or combination and/or kit of the invention is at least about 0.2% (w/w) inclusive.
  • the concentration of the Dead Sea extract (e.g., Dead Sea water) in the composition and/or formulation and/or combination and/or kit of the invention is at least about 0.4% (w/w) inclusive.
  • the at least one Rumex plant extract is a Rumex occidentalis plant extract.
  • the Rumex extract is an aqueous extract.
  • the concentration of the Rumex extract e.g., Rumex Occidentalis extract
  • the concentration of the Rumex extract is at between about 0.01% to about 3.00% (w/w), inclusive the end points values.
  • the Thioredoxin protein/polypeptide may be produced utilizing wild plants, whole non-GM plants, as bio-factories: the synthetic gene cloning may comprise plant seeding, plant cultivation and vegetalized plasmid followed by mechanical introduction of synthetic transcript, scale-up of expression system and harvesting, plant (e.g., leave extract or any other part thereof), isolation, purification and analysis.
  • the plant-Thioredoxin-1 is the commercially available PUREOXINTM (by LipoTrue).
  • the Thioredoxin polypeptide is of the SEQ ID NO. 1.
  • the Thioredoxin polypeptide may be formulated with at least one additive.
  • the additive is a stabilizer, a diluent, a carrier, a filler, an antioxidant or any combination thereof.
  • the additive is an inert additive.
  • the concentration of the Thioredoxin polypeptide (e.g., protein) in the composition and/or formulation and/or combination and/or kit of the invention is about 0.40 % (w/w).
  • the concentration of the Dead Sea extract (e.g., Dead Sea water) in the composition and/or formulation and/or combination and/or kit of the invention is at between about 0.1 % to about 5.00% (w/w), at times at between about 0.1 % to about 2.40% (w/w), at times between about 0.1% to about 2.00% (w/w), at times between about 0.1% to about 1.50% (w/w), at times between about 0.1% to about 1.00% (w/w), inclusive the end points values
  • the concentration of the at least one extract of the Rumex extract (e.g., Rumex Occidentalis extract) in the composition and/or formulation and/or combination and/or kit of the invention is at between about 0.05% to about 5.00% (w/w), at times at between about 0.05% to about 3.00% (w/w), at times at between about 0.05% to about 2.00% (w/w) inclusive the end points values
  • composition/combination of the invention is formulated as an emulsion.
  • the additive may be any one of the above noted additives or any combination thereof.
  • the additive may be any one of a stabilizer, an adjuvant, an excipient, a diluent, a carrier, a filler, an antioxidant or any combination thereof.
  • the inert additive is an emollient, being selected from vegetable and animal fats and oils such as castor oil, hydrogenated castor oil, cocoa butter, safflower oil, cottonseed oil, corn oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil, squalene, phytosqalene, kikui oil, chamomilla recutita (matricaria) flower oil, hypericum perforatum oil, soybean oil and vitis vinifera (grape) seed oil; acetoglyceride esters, such as acetylated monoglycerides; alkyl esters of fatty acids having 10 to 24 carbon atoms which include, but are not limited to, methyl, isopropyl, and butyl esters of fatty acids such as hexyl laurate, isohexyl laurate, ethylhexyl palmitate, isohexyl palmitate, isopropyl, iso
  • compositions/combination/formulation/kits of the invention are skin-care or dermo-pharmaceutical compositions (including, e.g., toiletries, health and beauty aids and cosmeceuticals) used for cosmetic and personal skin-care applications.
  • the present invention provides a composition and/or a combination and/or a kit for use in treating and/or preventing at least one disease or disorder of the skin.
  • the present invention provides a composition and/or a combination and/or a kit for use in treating and/or preventing inflammation of the skin of a subject.
  • the present invention provides a method for treating and/or preventing inflammation of the skin of a subject, wherein said method comprises topical application of a composition and/or a combination and/or the ingredients comprised within a kit according to the invention onto the skin of a subject.
  • the symptoms or signs of skin aging are changes to the color or irregularities in the pigmentation.
  • the methods/uses disclosed herein are therapeutic methods/uses e.g., associate with pathological skin conditions. In some embodiments the methods disclosed herein are non-therapeutic methods e.g., associated with normal skin conditions.
  • composition/combinations of the invention are formulated for use in the treatment of a disease or disorder.
  • compositions/combinations/formulations/kits of the invention are devoid of an extract of the Dunaliella alga.
  • compositions/combinations/formulations/kits of the invention are devoid of an extract selected from the group consisting of: an extract of the Apple of Sodom (AoS) (Calotropis Procera ,' Myrrh tree extract; Silybum extract; Jujube extract; an extract of Haloarchaea; and any combination thereof.
  • AoS Apple of Sodom
  • Product name Dead Sea Works LTD.
  • the product comprises the following ions: Mg +2 (92,500 mg/L), Ca +2 (38,000 mg/L), K + (1,400 mg/L), Na + (2,000 mg/L), Sr +2 (800 mg/L), Cl” (345,000 mg/L) and Br" (11,500 mg/L).
  • Figure 12 illustrates the IL-8 level in culture media of HOSC model after 16 days of incubation and irradiation with UVA 27 mJ7cm2.
  • the HSOC was topically applied with Arbutin, Complex (with no dilution), PUREOXIN, Tyrostat and Osmoter.
  • EMBODIMENT 17 The composition according to EMBODIMENT 16, wherein said plant-Thioredoxin-1 is Oligopeptide-4 (INCI).
  • said at least one Thioredoxin polypeptide is present in said composition at a concentration of between about 0.01% (w/w) to about 5.0 % (w/w), e.g., between about 0.01% (w/w) to about 4.0 % (w/w).
  • said at least one Thioredoxin polypeptide comprises one or more conventional tags.
  • EMBODIMENT 49 The combination according to any one of EMBODIMENTS 28 to
  • At least one Thioredoxin polypeptide is the commercially available plant- Thioredoxin-1 PUREOXINTM
  • EMBODIMENT 52 The combination according to any one of EMBODIMENTS 28 to
  • Dead Sea extract is present in said combination at a concentration of between about 0.01% (w/w) to about 5.0 % (w/w) (out of the total weight of the combination), e.g., between about 0.01% (w/w) to about 2.5 % (w/w) (out of the total weight of the combination).
  • EMBODIMENT 53 The combination according to any one of EMBODIMENTS 28 to
  • said at least one Thioredoxin polypeptide is present in said combination at a concentration of between about 0.01% (w/w) to about 5.0 % (w/w) (out of the total weight of the combination), e.g., between about 0.01% (w/w) to about 4.0 % (w/w) (out of the total weight of the combination).
  • EMBODIMENT 72 The kit according to any one of EMBODIMENTS 55 to 70, wherein said at least one Thioredoxin polypeptide comprises the SEQ ID NO. 1, is of the SEQ ID NO. 1 or is a derivative of the SEQ ID NO. 1.
  • EMBODIMENT 77 The kit according to any one of EMBODIMENTS 55 to 76, wherein said at least one Thioredoxin polypeptide is formulated with at least one additive.
  • EMBODIMENT 94 The method according to EMBODIMENT 93, wherein said protecting and/or improving and/or preventing and/or treating are associated with inhibition of melanin synthesis induced by said topical application.
  • EMBODIMENT 95 The composition according to any one of EMBODIMENTS 1 to 27, the combination according to any one of EMBODIMENTS 28 to 54 or the kit according to any one of EMBODIMENTS 55 to 81, for use in improving one or more of skin glow, lucent, radiance, anti-pigmentation, even tone and clear.
  • EMBODIMENT 98 The composition, combination or kit for use according to EMBODIMENT 97, wherein said improving is associated with inhibition of melanin synthesis induced by said topical application.
  • EMBODIMENT 105 A method for treating and/or preventing a disease or disorder of the skin of a subject, wherein said method comprises topical application of the composition according to any one of EMBODIMENTS 1 to 27, the combination according to any one of EMBODIMENTS 28 to 54 or the ingredients comprised within the kit according to any one of EMBODIMENTS 55 to 81, onto the skin of a subject.
  • EMBODIMENT 111 A method for treating and/or preventing inflammation of the skin of a subject, wherein said method comprises topical application of the composition according to any one of EMBODIMENTS 1 to 27, the combination according to any one of EMBODIMENTS 28 to 54 or the ingredients comprised within the kit according to any one of EMBODIMENTS 55 to 81, onto the skin of a subject.
  • EMBODIMENT 15A The composition according to any one of EMBODIMENTS 1A to 14A, wherein said at least one Thioredoxin polypeptide is a synthetic protein obtainable (or obtained) by gene cloning utilizing a plant (e.g., the plant Nicotiana benthamiana).
  • a plant e.g., the plant Nicotiana benthamiana.
  • EMBODIMENT 16A The composition according to any one of EMBODIMENTS 1A to 15 A, wherein said at least one Thioredoxin polypeptide is the plant- Thioredoxin-1 (plant- TRX-1).
  • EMBODIMENT 22A The composition according to any one of EMBODIMENTS 1A to 21A, wherein said at least one Thioredoxin polypeptide is the commercially available plant-Thioredoxin-1 PUREOXINTM.
  • EMBODIMENT 29A The composition according to any one of EMBODIMENTS 1A to 27A, for use in topical application.
  • EMBODIMENT 39A A method (therapeutic or non-therapeutic) for one or more of protecting and/or improving the state of the skin, and preventing and/or treating imperfections of the skin of a subject, wherein said method comprises topical application of the composition according to any one of EMBODIMENTS 1A to 27A, onto the skin of a subject.
  • EMBODIMENT 43A The composition according to any one of EMBODIMENTS 1A to 27A, for use in a method of improving one or more of skin glow, lucent, radiance, antipigmentation, even tone and clear, wherein said method comprises topical application of said composition onto the skin of a subject.
  • EMBODIMENT 60A The composition according to any one of EMBODIMENTS 1A to 27A, for use in a method of inhibiting and/or reducing skin melanin formation wherein said method comprises topical application of said composition onto the skin of a subject.
  • EMBODIMENT 61A A method (therapeutic or non-therapeutic) of inhibiting and/or reducing skin melanin formation, wherein said method comprises topical application of the composition according to any one of EMBODIMENTS 1 A to 27 A, onto the skin of a subject.
  • EMBODIMENT 5B The combination according to any one of EMBODIMENTS 2B to 4B, wherein the Dead Sea water comprises Ca +2 , CT, Mg +2 , Na + , K + and Br".
  • EMBODIMENT 37B The combination according to any one of EMBODIMENTS IB to 27B, for use in a method for one or more of protecting and/or improving the state of the skin, and preventing and/or treating imperfections of the skin of a subject, wherein said method comprises topical application of said combination onto the skin of a subject.
  • EMBODIMENT 38B The combination for use according to EMBODIMENT 37B, wherein said protecting and/or improving and/or preventing and/or treating are associated with inhibition of melanin synthesis induced by said topical application.
  • EMBODIMENT 43B The combination according to any one of EMBODIMENTS IB to 27B, for use in a method of improving one or more of skin glow, lucent, radiance, antipigmentation, even tone and clear, wherein said method comprises topical application of combination onto the skin of a subject.
  • EMBODIMENT 44B The combination for use according to EMBODIMENT 43B, wherein said improving is associated with inhibition of melanin synthesis induced by said topical application.
  • EMBODIMENT 47B The combination according to any one of EMBODIMENTS IB to 27B, for use in treating and/or preventing at least one disease or disorder of the skin.
  • EMBODIMENT 48B The combination for use according to EMBODIMENT 47B, wherein said treating and/or preventing is associated with one or more of inhibition of melanin synthesis and inflammation inhibition induced by topical application of said combination onto the skin.
  • EMBODIMENT 54B The combination for use according to EMBODIMENT 53B, wherein said treating and/or preventing is associated with reduction in IL-8 skin levels induced by topical application of said combination onto the skin.
  • EMBODIMENT 60B The combination according to any one of EMBODIMENTS IB to 27B, for use in a method of inhibiting and/or reducing skin melanin formation wherein said method comprises topical application of said combination onto the skin of a subject.
  • EMBODIMENT 61B A method (therapeutic or non-therapeutic) of inhibiting and/or reducing skin melanin formation, wherein said method comprises topical application of the combination according to any one of EMBODIMENTS IB to 27B onto the skin of a subject.
  • EMBODIMENT 63B Use of the combination according to any one of EMBODIMENTS IB to 27B in the manufacture of a pharmaceutical formulation or a skin care formulation.
  • EMBODIMENT 1C A kit comprising (i) at least one Dead Sea extract, (ii) at least one extract of the plant Rumex, and (iii) at least one Thioredoxin polypeptide, wherein each of components (i), (ii) and (iii), independently of the other, is formulated in admixture with one or more of an adjuvant, an excipient, a diluent or a carrier (being a pharmaceutically acceptable and/or a cosmetically acceptable adjuvant, excipient, diluent or carrier); and wherein each of (i), (ii) and (iii) are provided in a form that is suitable for concomitant administration with the other.
  • EMBODIMENT 2C The kit according to EMBODIMENT 1C, wherein said Dead Sea extract is a mixture of natural materials obtained from the waters of the Dead Sea, and/or the mud surrounding the Dead Sea and/or the soil bed of the Dead Sea.
  • EMBODIMENT 3C The kit according to EMBODIMENT 1C, wherein said Dead Sea extract is the saline waters obtained from the Dead Sea.
  • EMBODIMENT 10C The kit according to any one of EMBODIMENTS 1C to 9C, wherein said at least one one extract of the plant Rumex is formulated with at least one additive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne des compositions et/ou des associations comprenant au moins un extrait de mer morte, au moins un extrait de rumex végétal et au moins un polypeptide de thiorédoxine. La présente divulgation concerne en outre des kits comprenant au moins un extrait de mer morte, au moins un extrait du rumex végétal et au moins un polypeptide de thiorédoxine. Des méthodes utilisant les compositions et/ou associations et/ou kits sont également divulguées. Des utilisations de celles-ci, par exemple, en tant que produit lumineux pour la peau et anti-pigmentation de la peau, sont en outre divulguées.
PCT/IL2023/050559 2022-05-31 2023-05-31 Compositions de soins de la peau WO2023233405A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263347199P 2022-05-31 2022-05-31
US63/347,199 2022-05-31

Publications (1)

Publication Number Publication Date
WO2023233405A1 true WO2023233405A1 (fr) 2023-12-07

Family

ID=86760248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2023/050559 WO2023233405A1 (fr) 2022-05-31 2023-05-31 Compositions de soins de la peau

Country Status (1)

Country Link
WO (1) WO2023233405A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521267B1 (en) * 1998-06-08 2003-02-18 Fytokem Prtoducts, Inc. Tyrosinase inhibitors from plants
WO2005121329A2 (fr) * 2004-06-11 2005-12-22 Syngenta Limited Procede permettant d'ameliorer un etat inflammatoire de la peau
US20140212513A1 (en) * 2013-01-29 2014-07-31 Ahava - Dead Sea Laboratories Ltd. Topical compositions comprising dead sea water and uses thereof
JP2016003198A (ja) * 2014-06-16 2016-01-12 株式会社ファンケル カリクレイン７産生促進剤
WO2022013870A1 (fr) * 2020-07-14 2022-01-20 Seacret Spa Ltd. Extrait de solvant polaire de boue de mer morte, composition cosmétique et pharmaceutique, et leurs utilisations pour le soin et la protection de la peau, du cuir chevelu et des cheveux

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521267B1 (en) * 1998-06-08 2003-02-18 Fytokem Prtoducts, Inc. Tyrosinase inhibitors from plants
WO2005121329A2 (fr) * 2004-06-11 2005-12-22 Syngenta Limited Procede permettant d'ameliorer un etat inflammatoire de la peau
US20140212513A1 (en) * 2013-01-29 2014-07-31 Ahava - Dead Sea Laboratories Ltd. Topical compositions comprising dead sea water and uses thereof
JP2016003198A (ja) * 2014-06-16 2016-01-12 株式会社ファンケル カリクレイン７産生促進剤
WO2022013870A1 (fr) * 2020-07-14 2022-01-20 Seacret Spa Ltd. Extrait de solvant polaire de boue de mer morte, composition cosmétique et pharmaceutique, et leurs utilisations pour le soin et la protection de la peau, du cuir chevelu et des cheveux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARISSE G MENDOZA ET AL: "A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos", INTERNATIONAL JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, UK, vol. 53, no. 11, 30 September 2014 (2014-09-30), pages 1412 - 1416, XP071190379, ISSN: 0011-9059, DOI: 10.1111/IJD.12690 *
FERREIRA MARTA SALVADOR ET AL: "Trending Anti-Aging Peptides", COSMETICS, vol. 7, no. 4, 1 December 2020 (2020-12-01), pages 91, XP055815937, DOI: 10.3390/cosmetics7040091 *
MA'OR Z ET AL: "Skin smoothing effects of Dead Sea minerals: comparative profilometric evaluation of skin surface", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 19, no. 3, 28 June 2008 (2008-06-28), pages 105 - 110, XP071468822, ISSN: 0142-5463, DOI: 10.1111/J.1467-2494.1997.TB00173.X *
UNKNOWN: "Pureoxin(TM) - More than Illuminating Plant TRX-1", 6 September 2023 (2023-09-06), pages 1 - 2, XP093079678, Retrieved from the Internet <URL:https://lipotrue.com/products/pureoxin/> [retrieved on 20230906] *

Similar Documents

Publication Publication Date Title
EP2174648B1 (fr) Compositions de soins pour la peau et leurs utilisations
ES2689715T3 (es) Composiciones para tratamiento de la piel y métodos
CN111971022B (zh) 组合物用于防止或减缓炎症迹象出现的用途
WO2002047656A1 (fr) Compositions pouvant retarder le vieillissement de la peau
KR20110086894A (ko) 폐각의 알카리성 분말 그리고 칼슘용액을 포함하는 피부 외용제 조성물
FR2880802A1 (fr) Composition cosmetique ou dermopharmaceutique contenant un extrait d&#39;euglene
KR20130022471A (ko) 녹차 성분을 함유하는 화장료 조성물
WO2012143364A2 (fr) Composition cosmétique à utiliser pour augmenter la synthèse de collagène dans les cellules de la peau
JP7210814B2 (ja) シマレンガタケを培養するための方法
CN109330954B (zh) 美白亮肤水及其制备方法和酪氨酸酶抑制剂
KR20230048515A (ko) 천연 스킨케어 조성물
JP7446743B2 (ja) ピキア・アノマーラとレチノールとを含む局所用組成物
WO2006101119A1 (fr) Promoteur de synthese du collagene
EP3305370A1 (fr) Activateur d&#39;autophagie des algues
CN118176005A (zh) 用于护肤和伤口治疗的生物表面活性剂制剂
WO2023233405A1 (fr) Compositions de soins de la peau
JP2002370962A (ja) 美白用化粧料および皮膚老化防止・改善用化粧料
JP5423002B2 (ja) 亜鉛を有効成分として含有するコラーゲン合成促進剤
JP5366358B2 (ja) 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法
KR101252468B1 (ko) 피부 트러블 개선용 화장품 조성물
JP2018516878A (ja) ゲンチオピクロシドを含まないゲンチアナ抽出物
WO2008104570A2 (fr) Formulation visant à accroître l&#39;activité d&#39;un extrait végétal pour usage cosmétique et préparation cosmétique contenant cette formulation
CN111936208A (zh) 新型组合物用于防止或减缓与过量皮脂的存在相关的不美观迹象出现的用途
KR100427556B1 (ko) 루시놀을 함유하는 화장료 조성물
US11633425B2 (en) Anti-glycation compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23730219

Country of ref document: EP

Kind code of ref document: A1